Aliskiren-containing medications-including Amturnide, Tekturna, Tektuma HCT, Teamlo, and Valturna-are direct renin inhibiters used to treat hypertension. These drugs work by decreasing chemicals that cause the blood vessels to tighten. Often these drugs are used in combination with angiostensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Recently, the Federal Drug Administration (FDA) has reported that these drug combinations can cause problems and should not be used in patients with diabetes or moderate to severe renal impairments.
GlaxoSmithKline has decided to recall 394,230 bottles of its DynaCirc CR from the United States market. DynaCirc CR, a drug used to treat hypertension, is being pulled from the market due to inconsistent packaging practices. Novartis, the drug's manufacturer, has had issues with the integrity of it packaging out of its Lincoln, Nebraska plant. The packaging problems were identified by the United States Food and Drug Administration (FDA). Among the chief concerns cited by FDA inspectors were reports of tablets of certain medicines being placed in bottles labeled for other products. GlaxoSmithKline, a London-based company, said it issued the voluntary recall of all bottles of DynaCirc CR remaining in the United States market from wholesalers, pharmacies, and hospitals. Reports of adverse events do not exist at this point but Glaxo moved forward with the recall as a precautionary measure. As a result of the recall, the drug will not be available to patients, however there are alternative treatments available to patients currently being treated with DynaCirc.